Lombardi Center for Cancer Drug Discovery at Georgetown University
The NCI CBC center, Lombardi Center for Cancer Drug Discovery (LCCDD), operates under the umbrella of Georgetown University’s Lombardi Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center. Louis M. Weiner, MD., is the director of the cancer center. The LCCDD is directed by Sivanesan Dakshanamurthy, PhD, MBA.
The LCCDD center comprises three technology cores:
- Computational Aided Drug Design (CADD)
- Structural Biology Biophysical Surface Plasmons Resonance (SPR)
- Cancer Cell Biology (CCB)
The technology cores possess specialized and unique technical expertise and capabilities, from computational hit-to-lead optimization to SPR binding kinetics to in vivo PDX and organoid models that can be deployed to advance the NCI CBC unmet need projects.
The LCCDD possesses a broad range of fundamental and specialized capabilities, expertise and skills and takes advantage of the outstanding core facilities and resources established at Georgetown Lombardi. We have validated protocols (including undruggable targets) for target mechanisms, hit assessment, triage, and lead optimization for target affinity, potency, selectivity, and efficacy leading toward the IND enabling studies.
Sivanesan Dakshanamurthy, PhD, MBA
New Research Building, EP22
3970 Reservoir Road, N.W., Washington D.C. 20057
The LCCDD Center is awarded by the Chemical Biology Consortium within the NCI NExT Program Contract #S22-015.